• 1
    Kwast BE. Postpartum haemorrhage: its contribution to maternal mortality. Midwifery 1991; 7: 6470.
  • 2
    Fawcus S, Mbizvo MT, Lindmark G, Nystrom L. Maternal mortality study group. Community based investigation of causes of maternal mortality in rural and urban Zimbabwe. Cent Afr J Med 1995; 41: 105113.
  • 3
    Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991-1993. London : HMSO, 1996: 3247.
  • 4
    Elbourne D, Prendiville W, Chalmers I. Choice of oxytocic preparation for routine use in the management of third stage of labour. An overview of evidence from controlled trials. Br J Obstet Gynuecol 1988; 95: 1730.
  • 5
    Prendiville WJ. The prevention of post partum haemorrhage: optimising routine management of the third stage of labour. Eur J Obstet Gynecol Reprod Biol 1996; 69: 1924.
  • 6
    Nordstrom L, Fogelstam G, Larsson A, Rydhstroem H. Routine oxytocin in the third stage of labour: a placebo controlled trial. Br J Obstet Gynaecol 1997; 104: 781786.
  • 7
    Van Selm M, Kanhai HHH, Keirse MJNC. Preventing the recurrence of atonic postpartum haemorrhage, a double-blind trial. Acta Obstet Gynecol Scand 1995; 74: 270274.
  • 8
    Jacobs M, Arias F. Intramyometrial prostaglandin F2 in the treatment of severe postpartum hemorrhage. Obstet Gynecol 1980; 55: 665666.
  • 9
    De Groot ANJA, van Roosmalen J, van Dongen PWJ, Borm GF. A placebo-controled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstet Gynecol Scand 1996; 75: 464468.
  • 10
    Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet, 338: 12331236.
  • 11
    Windrim R, Bennett K, Mundle W, Young DC. Oral administration of misoprostol for labor induction: a randomized control trial. Obstet Gynecol 1997; 89: 392397.
  • 12
    Senior J, Marshall K, Sangha R, Clayton JK. In vitro characterisition of prostanoid receptors on human myometrium at term pregnancy. Br J Pharm 1993; 108: 501506.
  • 13
    El-Rafacy H, OBrien P, Morafa W, Walder J, Rodeck C. Misoprostol for third stage of labour. Lancet 1996; 347: 1257.
  • 14
    El-Refaey H, O'Brien P, Morafa W, Walder J, Rodeck C. Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol 1997; 104: 336339.
  • 15
    Chong YS, Chua S, Arulkumaran S. Can Oral Misoprostol be used as an alternative to parented oxytocics in the active management of the third stage of labour? A preliminary study of its effect on the postpartum uterus [abstract]. The Royal Australian and Royal New Zealand Colleges of Obstetricians and Gynaecologists Combined Scientific Meeting, Brisbane 28 April–2 May, 1997; p. 61.
  • 16
    Pritchard JA, Baldwin RM, Dickey JC, Wiggins KM. Blood volume changes in pregnancy and the puerperium. Am J Obster Gynecol 1962; 84: 12711282.
  • 17
    Bloomfield TH, Gordon H. Reaction to blood loss at delivery. J Obstrt Gynaecol 1990; 10: S13S16.
  • 18
    Khan GQ, John IS, Chan T, Wani S, Hughes AO, Stirrat GM. Abu Dabi third stage trial: oxytocin versus Syntometrine in the active management of the third stage of labour. Eur J Obstet Gynecol und Reprod Biol, 58: 147151.
  • 19
    McDonald SJ, Prendiville W, Blair E. Randomised controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of the third stage of labour. BMJ: 307: 11671171.
  • 20
    Prendiville WJ, Harding JE, Elbourne DR, Stirrat GM. The Bristol third stage trial: active vs physiological management of the third stage of labour. BMJ 1988; 297: 12951300.
  • 21
    Begley CM. A comparison of ‘active’ and ‘physiological’ management of third stage of labour. Midwifery 1990 6 1317.